NASDAQ:ISEE IVERIC bio (ISEE) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free ISEE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$39.95▼$39.9550-Day Range$36.90▼$39.9552-Week Range$9.39▼$39.99VolumeN/AAverage Volume3.62 million shsMarket Capitalization$5.50 billionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock Analysis Get IVERIC bio alerts: Email Address IVERIC bio MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside27.4% Downside$29.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.77) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.02 out of 5 starsMedical Sector938th out of 938 stocksBiotechnology Industry47th out of 47 stocks 1.0 Analyst's Opinion Consensus RatingIVERIC bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.00, IVERIC bio has a forecasted downside of 27.4% from its current price of $39.95.Amount of Analyst CoverageIVERIC bio has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ISEE. Previous Next 0.0 Dividend Strength Dividend YieldIVERIC bio does not currently pay a dividend.Dividend GrowthIVERIC bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ISEE. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for ISEE on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IVERIC bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of IVERIC bio is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IVERIC bio are expected to grow in the coming year, from ($1.77) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IVERIC bio is -22.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IVERIC bio is -22.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIVERIC bio has a P/B Ratio of 9.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About IVERIC bio Stock (NASDAQ:ISEE)IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… ISEE Stock News HeadlinesMarch 10, 2024 | investing.comAstellas Pharma Inc (ALPMY)December 15, 2023 | msn.comApellis falls on potential EU snub for eye therapy (update)March 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!December 7, 2023 | seekingalpha.comAkoya Biosciences: 2024 Could Be The Year To Own Their StockDecember 1, 2023 | msn.comApellis adds safety warning to eye therapyJuly 11, 2023 | finance.yahoo.comAstellas Completes Acquisition of Iveric BioJune 30, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Its Hold Rating for IVERIC bio (ISEE)May 30, 2023 | seekingalpha.comIveric bio, Still A 5+% OpportunityMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!May 30, 2023 | finance.yahoo.comAnnexon (ANNX) Stock Down More Than 50% Last Week: Here's WhyMay 23, 2023 | seekingalpha.comBayer, Amgen looked at Iveric before agreeing to Astellas sale - reportMay 17, 2023 | msn.comUnusual Call Option Trade in IVERIC bio (ISEE) Worth $1,780.50KMay 11, 2023 | fool.comIVERIC Bio (NASDAQ: ISEE)May 9, 2023 | msn.comTD Cowen Downgrades IVERIC bio (ISEE)May 2, 2023 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.May 2, 2023 | benzinga.comMoore Kuehn Encourages ISEE, MDWT, CBOF, and SGEN Investors to Contact Law FirmMay 1, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating IVERIC bio, Inc. BuyoutMay 1, 2023 | benzinga.comCheck Out What Whales Are Doing With ISEEMay 1, 2023 | finance.yahoo.comAstellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'May 1, 2023 | finance.yahoo.comBiotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas PharmaMay 1, 2023 | finance.yahoo.comThese Stocks Are Moving the Most Today: First Republic, JPMorgan, Iveric Bio, SoFi, ON Semi, and MoreMay 1, 2023 | finance.yahoo.comFirst Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top StoriesMay 1, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether IVERIC bio, Inc. has obtained a Fair Price in its transaction with AstellasMay 1, 2023 | technews.tmcnet.comISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to ShareholdersMay 1, 2023 | marketwatch.comIveric Bio Shares Rise Premarket on Takeover by Astellas >ISEEMay 1, 2023 | msn.comIveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.May 1, 2023 | finance.yahoo.comJapan’s Astellas to buy US biotech group Iveric Bio for $5.9bnSee More Headlines Receive ISEE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ISEE CUSIPN/A CIK1410939 Webivericbio.com Phone(609) 474-6755FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$29.00 High Stock Price Target$29.00 Low Stock Price Target$29.00 Potential Upside/Downside-27.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.00% Return on Assets-46.15% Debt Debt-to-Equity Ratio0.20 Current Ratio15.53 Quick Ratio15.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.43 per share Price / Book9.02Miscellaneous Outstanding Shares137,780,000Free Float134,063,000Market Cap$5.50 billion OptionableOptionable Beta1.06 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Glenn P. Sblendorio M.B.A. (Age 67)CEO & Director Comp: $1.36MDr. Pravin U. Dugel M.D. (Age 59)Pres & Director Comp: $984.82kMr. David F. Carroll M.B.A. (Age 57)Sr. VP, CFO & Treasurer Comp: $725.55kMr. Keith Westby M.B.A. (Age 48)Sr. VP & COO Comp: $701.68kMr. Christopher Paul Simms (Age 48)Sr. VP & Chief Commercial Officer Comp: $715.01kDr. Samir C. Patel (Age 62)Co-Founder and Consultant Dr. Xiao-Ping Dai Ph.D.Chief Technical OfficerMs. Kathy GalanteSr. VP of Investor Relations & Corp. CommunicationsMr. Todd D.C. AndermanSr. VP, Chief Legal Officer & Corp. Sec.Ms. Amy R. SheehanSr. VP & Chief HR OfficerMore ExecutivesKey CompetitorsRayzeBioNASDAQ:RYZBImmunoGenNASDAQ:IMGNArdelyxNASDAQ:ARDXSoleno TherapeuticsNASDAQ:SLNOBlueprint MedicinesNASDAQ:BPMCView All CompetitorsInsidersKeith WestbySold 20,000 sharesTotal: $789,000.00 ($39.45/share)Keith WestbySold 20,000 sharesTotal: $757,400.00 ($37.87/share)David Francis CarrollSold 63,500 sharesTotal: $2.35 M ($37.04/share)Keith WestbySold 20,000 sharesTotal: $742,400.00 ($37.12/share)David Francis CarrollSold 48,171 sharesTotal: $1.46 M ($30.21/share) ISEE Stock Analysis - Frequently Asked Questions Should I buy or sell IVERIC bio stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last twelve months. There are currently 8 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ISEE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISEE, but not buy additional shares or sell existing shares. View ISEE analyst ratings or view top-rated stocks. What is IVERIC bio's stock price target for 2024? 8 equities research analysts have issued 12-month price targets for IVERIC bio's shares. Their ISEE share price targets range from $29.00 to $29.00. On average, they predict the company's share price to reach $29.00 in the next year. This suggests that the stock has a possible downside of 27.4%. View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts. How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:ISEE) posted its quarterly earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.10. During the same quarter last year, the firm posted ($0.29) earnings per share. What ETFs hold IVERIC bio's stock? ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB), AltShares Event-Driven ET (EVNT) and Vanguard Russell 2000 Growth ETF (VTWG).Vanguard Russell 2000 ETF (VTWO). What is Glenn Spina's approval rating as IVERIC bio's CEO? 6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC). This page (NASDAQ:ISEE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.